Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort pMDI in COPD Exacerbations
NCT00419744Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2007
- Primary completion
- Aug 2009
- Modality
- Orthosteric Ligands
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of budesonide in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by AstraZeneca. Primary endpoints: Total Number of Chronic Obstructive Pulmonary Disease Exacerbations Per Patient-treatment Year at 12 months and Rate of Exacerbations Per Subject-year at 12 months. Started Jan 2007; status: completed.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00419744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00419744.